GlassScriptPhysician profile
James A Wilson
NPI 1144398140
$1,523.09
in general payments reported to CMS, 2019-2025
26 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $166 · 2021: $527 · 2022: $225 · 2023: $146 · 2024: $118 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $314.48 | 2019-2023 | Aimovig |
| Ucb, INC. | $145.84 | 2019-2025 | Rystiggo, Zilbrysq |
| Lilly USA, LLC | $114.74 | 2021-2024 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $97.62 | 2019-2024 | Austedo Xr |
| Sk Life Science, INC. | $80.17 | 2020-2021 | |
| Abbvie INC. | $72.60 | 2019-2022 | |
| Eisai INC. | $67.88 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $62.16 | 2019-2023 | Ultomiris |
| Biogen, INC. | $56.16 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $46.26 | 2019-2023 | Ongentys, Ingrezza |
| Emd Serono, INC. | $46.26 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $46.00 | 2021 | |
| Tanabe Pharma America, INC. | $39.08 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.84 | 2020 | |
| Pfizer INC. | $37.44 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.15 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $33.48 | 2019-2020 | |
| Genentech USA, INC. | $30.68 | 2019-2025 | Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $29.53 | 2021 | |
| Impel Pharmaceuticals INC. | $23.79 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.68 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $18.57 | 2021 | |
| Allergan, INC. | $18.17 | 2020 | |
| Amneal Pharmaceuticals LLC | $16.54 | 2025 | Crexont |
| Ironshore Pharmaceuticals INC. | $16.49 | 2024 | |
| Adamas Pharmaceuticals, INC. | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.